5 Ways Artificial Intelligence Is Changing the Pharma and Healthcare Industries

July 22, 2019

Forbes predicts that AI in healthcare will top US$1.7 billion by the end of the year. Download our free whitepaper today and learn the top 5 ways artificial intelligence is driving exciting change that will improve patient outcomes.

Spotlight

VHA Home HealthCare

GENESIS Pharma started its activity in pharmaceutical biotechnology in 1997, at a time when the industry was still at an early development stage, not only in Greece but also in Europe. The company's goal was to combine the rapid progress in science with a successful and innovative business venture, thus paving the way for the creation of a new market. Working with consistency and dedication to this end, GENESIS Pharma became the first Greek pharmaceutical company specializing in the promotion, sales and distribution of biopharmaceutical products and is currently the largest by turnover among Greek companies focusing on innovative branded medicines.

OTHER WHITEPAPERS
news image

Nanoform Management Presentation

whitePaper | May 24, 2022

Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics.

Read More
news image

How Cellular is Enabling the Digital Supply Chain

whitePaper | January 12, 2020

Supply chains grow more and more complex every day. In response, manufacturers and shippers have been eagerly exploring digital tools that provide actionable insight into the location and condition of in-transit goods. Although there are many technology options when it comes to building a digital supply chain, one type of solution stands out as the most reliable and cost-effective: cellular.

Read More
news image

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

Read More
news image

Characterization of Protein Aggregates and Other Particles in Biopharmaceuticals

whitePaper | July 8, 2022

Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.

Read More
news image

Discovering Effective Strategies for Sales and Marketing in the Face of Reduced Access to Oncologists

whitePaper | January 15, 2023

Oncology breakthroughs are currently fueling significant growth in the market, as well as the competition between pharmaceutical brands for market share. As increasingly individualized cancer treatments become available,

Read More
news image

Market Access Trends in the US, Europe, and Emerging Markets

whitePaper | November 14, 2022

Rising drug spending and increased desire for expenditure controls are consistent themes across the US, Europe, and emerging markets.

Read More

Spotlight

VHA Home HealthCare

GENESIS Pharma started its activity in pharmaceutical biotechnology in 1997, at a time when the industry was still at an early development stage, not only in Greece but also in Europe. The company's goal was to combine the rapid progress in science with a successful and innovative business venture, thus paving the way for the creation of a new market. Working with consistency and dedication to this end, GENESIS Pharma became the first Greek pharmaceutical company specializing in the promotion, sales and distribution of biopharmaceutical products and is currently the largest by turnover among Greek companies focusing on innovative branded medicines.

Events